Funding renewal will support development of cystic fibrosis and retinitis pigmentosa as well as contrast agents related to breast cancer surgery.

Case Western Reserve University School of Medicine and two of its spinouts, Copernicus Therapeutics and Polgenix, have landed an additional $3.9 million in funding from the Ohio Biomedical Research Commercialization Program (BRCP).

The grant will cover development of nanoparticles for treatment of cystic fibrosis and retinitis pigmentosa using gene therapy technology from Copernicus. It will also include commercialization of Polygenix’ two-photon ophthalmoscope for early detection of retinal disease and the advancement of contrast agents for the detection of clean margins during breast cancer surgery, which use PolyGenix technology.

Previous articleSciele and Addrenex Ink Second Hypertension Collaboration
Next articleLonza Reports Manufacturing Deal with Osiris and Facility Constructions